Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atomoxetine Hydrochloride Clear all
Completed Phase 4 Interventional

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957
View directory record Official record
Conditions
ADHD, Comorbid Alcohol Abuse
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
El Centro, California • Poway, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Atomoxetine for Freezing of Gait in Parkinson's Disease

NCT03651856
View directory record Official record
Conditions
Parkinson's Disease, Freezing of Gait
Interventions
ATM FOG in PD
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
ABT-894, atomoxetine, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

NCT00498173
View directory record Official record
Conditions
Autism
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 26, 2026, 5:47 PM EDT
Completed No phase listed Observational

Safety Study of Atomoxetine and Cerebrovascular Outcomes

NCT00634439
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions
atomoxetine, Stimulants, No intervention (general population)
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 26, 2026, 5:47 PM EDT
Recruiting Phase 4 Interventional

Endotype DIrected Treatment for OSA in Down Syndrome

NCT07280468
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Down Syndrome
Interventions
ato-oxy, Oxygen
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

NCT00510276
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 30 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Los Angeles, California • Rolling Hills Est., California • Spring Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Not applicable Interventional Results available

A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment

NCT01802515
View directory record Official record
Conditions
Cocaine Dependence, Opiate Dependence
Interventions
Atomoxetine, low dose, Atomoxetine, high dose, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 26, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

Atomoxetine PBPK-PD Clinical Study

NCT03154359
View directory record Official record
Conditions
ADHD
Interventions
Atomoxetine Hydrochloride
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

NCT00218322
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

Atomoxetine in the Treatment of Binge Eating Disorder

NCT00327834
View directory record Official record
Conditions
Binge-eating Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

NCT01678209
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

Atomoxetine Pilot Study in Preschool Children With ADHD

NCT00517647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ATMX
Drug
Lead sponsor
University of Arizona
Other
Eligibility
3 Years to 5 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Long-Term, Open Label Atomoxetine Study

NCT00190684
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 18 Years
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2011 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

NCT03091400
View directory record Official record
Conditions
Memory Disorders, Multiple Sclerosis
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830
View directory record Official record
Conditions
Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Interventions
Accelerometer, placebo pill, Midodrine or atomoxetine pill
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional Results available

Safety Assessment of Atomoxetine With MA IV Administration

NCT01019707
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Atomoxetine, then Placebo, Placebo, then Atomoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, atomoxetine, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

NCT03919955
View directory record Official record
Conditions
Sleep Apnea
Interventions
Atomoxetine, Oxybutynin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rescue Pharmacotherapy for OSA

NCT05293600
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

NCT01738191
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 26, 2026, 5:47 PM EDT